Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 5822

Sort by

Sort Order Select

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Expect the unexpected

Didier Blaise

Blood (2021) 137 (23): 3163–3164.

https://doi.org/10.1182/blood.2021011368

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

A combination of cyclophosphamide and interleukin-2 allows CD4 + T cells converted to Tregs to control scurfy syndrome

Blood (2021) 137 (17): 2326–2336.

https://doi.org/10.1182/blood.2020009187

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood (2019) 134 (26): 2361–2368.

https://doi.org/10.1182/blood.2019001641

Published: 2019

Includes: Supplemental data

Journal Articles

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Shannon R. McCurdy, Leo Luznik

Blood (2019) 134 (21): 1802–1810.

https://doi.org/10.1182/blood.2019001323

Published: 2019

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Julie Devin, PharmD, Tatiana Cañeque, Yea-Lih Lin, PhD, Guillaume Cartron, Philippe Pasero, PhD, Caroline Bret, PhD PharmD, Raphael Rodriguez, Jerome Moreaux, PhD

Blood (2019) 134 (Supplement_1): 3960.

https://doi.org/10.1182/blood-2019-129954

Published: 2019

Journal Articles

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Nikesh Shah, MD, Franco Castillo-Tokumori, MD, Julio C. Chavez, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 3991.

https://doi.org/10.1182/blood-2019-127291

Published: 2019

Journal Articles

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Shilpa Paul, PharmD, Koji Sasaki, MD, J Michael Savoy, PharmD, Adam Dipippo, PharmD, Nadya Jammal, PharmD, Kayleigh Marx, PharmD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3810.

https://doi.org/10.1182/blood-2019-130284

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4003.

https://doi.org/10.1182/blood-2019-130133

Published: 2019

Journal Articles

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A. Samer Al-Homsi, MD, Enkhtsetseg Purev, MD PhD, Philippe Lewalle, Maher Abdul-Hay, MD, Daniel A Pollyea, MD, Adriano Salaroli, MD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Fabian Borghese, Caroline Lonez, PhD, Nathalie Braun, Florence Renard, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3844.

https://doi.org/10.1182/blood-2019-128267

Published: 2019

NARROW

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Expect the unexpected

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

A combination of cyclophosphamide and interleukin-2 allows CD4 + T cells converted to Tregs to control scurfy syndrome

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

The different flavors and splices of MCL

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only